A new scientific study has found that bio detection dogs trained by the Great Horwood-based charity Medical Detection Dogs have a very high level of accuracy when asked to identify bacteria associated with serious lung infections.
The findings, published in the European Respiratory Journal, show that medical detection dogs can differentiate between Pa (Pseudomonas aeruginosa) and other CF (cystic fibrosis) bacterial pathogens by sniffing bacteria grown in a nutrient liquid.
The study’s authors – Imperial College, London and the Cystic Fibrosis Trust – conclude that, compared with existing technologies, dogs may ultimately prove more sensitive or more affordable for screening lower airway infection in cystic fibrosis.
Although Pa can be successfully eradicated it frequently reoccurs and develops resistance to antibiotics.
Chronic Pa is closely linked with faster lung function decline and earlier mortality.
The heavy antibiotic burden imposed upon patients and the resulting bacterial resistance, allergies and toxicities compound the detrimental impact of the infection itself.
This is a particular problem for children with CF, as it is often harder to diagnose in them, but takes hold of the lungs and becomes extremely difficult to shift.
If they have symptoms, they are usually prescribed a broad spectrum antibiotic that will not work if the culprit is Pseudomonas.
Early detection will lead to them receiving a targeted antibiotic, stopping the bacteria taking hold.
Given the natural odour of Pa, the new study’s authors hypothesised that dogs can be trained to detect this bacterial organism.
As a first step they assessed the ability of four dogs to identify Pa from other CF bacteria.
The bacteria were grown in the lab, and then filtered out of the solution which was presented to the dogs.
In the trial, the dogs were trained and tested on customised sample presentation stands.
During training, correct identification of Pa samples was rewarded by an auditory click and food.
Once trained, dogs were presented with Pa-positive cultured samples, other cultured bacterial controls or sterile liquid in a random, computer-generated sequence.
A positive indication (when the dog either stopped or sat down) was rewarded if correct.
The samples were then presented in a double-blind testing scenario with four blind studies undertaken:
> Pa versus other bacteria familiar to the dogs, producing a mean sensitivity (correct signalling at a Pa sample) of 94.2% with a specificity of 98.5%
> Pa versus previously unencountered bacteria, with two of the three dogs maintaining sensitivity at above 90%
> Dilution testing - at dilutions of 1:1,000, sensitivity (93.8%) and specificity (94.9%) were consistently maintained
> Mixed, multi-organism cultures, still correctly identifying Pa with a sensitivity of 86.5% and a specificity of 84.1%
The study was supported by the Cystic Fibrosis Trust and conducted by Imperial College London and Royal Brompton Hospital, in collaboration with Medical Detection Dogs, who say they are ‘delighted’ that this rigorous scientific study has demonstrated the ability of the dogs they train to accurately detect possible indicators of infection and disease.
Professor Jane Davies from Imperial College London said: “This is a really exciting development.
“Advanced technology to detect infections, for example in breath, has proved difficult so far.
“The successful training of the dogs on cultured samples will now be used as the foundation for testing patient samples directly.
“People with CF could ultimately monitor their lung infections from home by sending in samples for the dogs to check.
“We are very grateful to those with CF, cared for by Royal Brompton Hospital, for providing samples for this project and to the CF Trust for their funding support of the next stage of this project as part of the Strategic Research Centre for Pseudomonas infection.”
Dr Claire Guest, chief executive and co-founder of Medical Detection Dogs added: “The findings of this world-first study into the ability of dogs to detect Pseudomonas are yet another indicator of their remarkable contribution to saving human lives.
“Pseudomonas is a condition that affects thousands of people each year in the UK alone.
“I can assure them that Medical Detection Dogs is working very hard to find effective, affordable and sustainable ways to manage their condition. “These trial results are just one more reason why dogs never cease to amaze me.
“They have a highly sensitive sense of smell, unfailing loyalty to their owners, and the ability to restore hope to many.”
Dr Janet Allen, director of strategic innovation at the Cystic Fibrosis Trust said: “A quick and easy way of detecting Pseudomonas would make a massive difference to people with cystic fibrosis and their families.
“Once it takes hold, it requires strong antibiotics that can require hospital stays and often carry significant side effects.
“Some antibiotic-resistant strains can even cause permanent, life-shortening lung damage.
“We’re delighted to fund the next steps of this work as part of our ‘Personalised approach to Pseudomonas’ strategic research centre, so we can build on this work and help people with cystic fibrosis live longer, healthier lives.”